The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug Report package.
Please note: there are various version of this report if you click on the file!
This is the second civil society-led monitoring report produced by Correlation – European Harm Reduction Network (C-EHRN). The purpose of this report is to enrich the information and knowledge base of harm reduction interventions in Europe from the viewpoint of civil society organisations. The Monitoring report gathers data on the experiences of harm reduction service providers and service users at ground level, building on a network of national Focal Points (FPs) in Europe. For the 2020 monitoring, C-EHRN includes 35 FPs in 34 countries. To get insight at the implementation level, and to profit from the experiences and expertise of FPs, the 2020 monitoring focuses mostly on cities rather than countries. The main areas monitored are: essential harm reduction services, overdose prevention, Hepatitis C, New drug Trends, Civil Society Involvement and COVID-19 impact on harm reduction services and people who use drugs.
The aim of this report is to provide an overview of generic national health emergency responses to public health threats and to identify mechanisms that may be applicable to synthetic opioid preparedness. This inventory will enable us to learn from generic health emergency crises, such as food-borne diseases, flew pandemics, and environmental crises, as well as from the health emergency program EU Joint Action SHARP.
The aim of this report is to provide an overview of synthetic opioid preparedness protocols and strategies of different EU Member States and to identify needs and challenges across the EU. This will be done by means of a review of the literature and a questionnaire to the EMCDDA Reitox Focal Points, both investigating existing practices of synthetic opioid preparedness. In addition to that, the findings will be discussed with key experts in the field to identify needs and challenges in synthetic opioid preparedness.
Over the past 15 years, an increasing use of opioids has been reported in the USA and Canada, coinciding with an increase in opioid addiction, opioid-related morbidity, and opioid-related mortality. Indeed, in the USA approximately 130 patients die from an overdose of prescription opioids each day. The opioid epidemic has been well documented in the USA and Canada, but fewer data are available for Europe.
For an over a decade up to 2017, Estonia has had the highest overdose death mortality in Europe. The use of (injected) fentanyl is a major contributor to the Estonian overdose death epidemic. Shutting down a major producer and distributor of illicit fentanyl has been extremely effective in curbing the number of overdose deaths. Unfortunately, this supply-side intervention came ten years into the epidemic, and might be difficult to replicate in settings with decentralized production. In areas faced by fentanyl we would recommend large-scale implementation of opiate substitution treatment and naloxone distribution, syringe service programs to provide for safer injecting and link to other services (high frequencies of fentanyl injection create high risk for HIV and HCV transmission), and programs, such as “Break the Cycle,” to reduce initiation into injecting drug use. Further, the means of responding to emerging substances should match the world in which different substances can be rapidly introduced, and where people who use drugs can change preferences based on market availability.
The fentanyl epidemic has been affecting Sweden since 2015. Since April 2015, 369 individuals have died, most of them men in the ages 25–38. The youngest victim is a three-year-old girl. This development has prompted a special effort against the phenomenon at the Intelligence Division of the National Operations Department of the Swedish Police Authority (the NOA Intelligence Division) and is also what prompts the need for this national picture.
Even if the prevalence of fentanyl analogues and the number of users are marginal, the situation is assessed to be the most serious development to date in the Swedish drug market. It is estimated that one in ten users die as a result of intoxication, and in October 2017, a higher number of individuals died of fentanyl toxicity than in road traffic. In addition, the fentanyl group (including the analogues) has surpassed heroin as the most lethal substance. Fentanyl analogues are generally extremely potent (up to 4 000 times as potent as pure heroin) and pose a danger also to individuals other than the users.
The number of opioid-related deaths in the United States is truly astounding. There were on the order of 50,000 opioid-involved overdose fatalities in 2018, which is roughly similar to the magnitude of deaths from HIV/AIDS at its peak in 1995 (Centers for Disease Control and Prevention, 2013; Ruhm, 2018; Ahmad et al., 2019). The rates of overdose fatalities involving heroin or other semisynthetic or natural opioids (which are mostly prescription drugs; see Appendix A for terms) have slowed in recent years and are now outnumbered two to one by overdoses involving synthetic opioids. Ciccarone (2017, p. 107) refers to a “triple wave epidemic:” The first wave was prescription opioids, the second wave was heroin, and the third—and ongoing—wave is synthetic opioids.
There are many different synthetic opioids, but analyses of death certificate records show that most synthetic opioid overdoses as of 2016 involve fentanyl (Hedegaard et al., 2018; Spencer et al., 2019). Similarly, drug seizure databases indicate a sharp rise in the number of exhibits containing fentanyl, from slightly fewer than 1,000 in 2013 to more than 59,000 in 2017 (U.S. Drug Enforcement Administration, 2018e), although some of that increase might be a function of greater law enforcement efforts aimed at detecting and seizing fentanyl and other synthetic opioids.
The current opioid crisis is a far-reaching drug and public health policy issue affecting several geographical regions. Since its appearance, endeavours have been undertaken both at the national and international level to develop integrated policy responses to address the crisis. Yet, despite some progress, the crisis continues both to expand geographically and to deepen in complexity with the emergence of a new generation of new psychoactive substances (NPS) with opioid effects, including substances belonging to chemical structural classes which were not significantly present on illicit drug markets previously. This evolution in chemical structural groups signals the potential development of similar new substances which may exacerbate the already significant challenges faced by public health and drug control systems. Additionally, the onset of the COVID-19 pandemic in late 2019 and early 2020 may further complicate and reshape existing trends in the crisis.
An update from the EU Early Warning System
New psychoactive substances are a broad range of drugs that are not controlled by the 1961 and 1971 United Nations drug control conventions but may pose similar threats to public health. Many of them are traded as ‘legal’ replacements to established controlled drugs such as cannabis, heroin, cocaine and MDMA.
Over the last decade, there has been a large increase in these substances as globalisation and new technology have allowed production to shift from small-scale illicit laboratories in Europe to commercial chemical and pharmaceutical operations in China that are capable of making hundreds of different substances on an industrial scale. Once in Europe, they are sold openly in branded products advertised as ‘legal highs’, under the guise of being ‘research chemicals’, and as ‘food supplements’, in attempts to make these substances attractive to users. They are also sold on the illicit drug market, either under their own names or passed off as established controlled drugs to unsuspecting users. In parallel with the growth in the range of substances and products that are offered, the consumer base has also grown and includes recreational users, chronic and marginalised drug users, those who self-medicate, and people wanting to improve how they look or their performance at work or when studying. The growth in the market is also reflected in a large increase in the number of seizures reported by law enforcement as well as in poisonings.
A growing number of highly potent substances that pose a high risk of acute poisoning are also being reported. These include synthetic cannabinoids, opioids, benzodiazepines and a range of other substances.
The COVID-19 pandemic has brought into sharp focus the importance of ‘complex, transboundary, multifactorial’ approaches to tackling health challenges, the need to strengthen health security and the interconnected nature of health in our globalised world.
The effect of the pandemic on the drug situation, including the new psychoactive substances market, is likely to become increasingly important as countries in Europe face the second wave of the outbreak during autumn and winter 2020 and into 2021.
This paper addresses the question of whether Europe is facing an opioid epidemic and utilizes data from the European monitoring system on opioid use, harms and availability, to help assess the situation. Data sources covering the last decade on overdose deaths, drug treatment entrants and drug-related emergencies suggest that the health burden associated with opioid use is mostly related to the consumption of heroin – and to a lesser extent diverted opioid substitution treatment medications – and that it is primarily affecting an ageing cohort of vulnerable users, with little evidence of an increase in initiation. While opioid-related deaths are currently at much lower levels than in the United States, they still represent a large preventable health burden with differences across EU countries. There is also increasing concern related to the high availability of heroin, illicitly produced synthetic opioids and diverted opioid pain medications on the European drugs market. Trends in the latter categories are poorly monitored and we may miss signs of emerging problems. Moreover, the economic recession following the COVID-19 pandemic has a potential to lead to resurgence in opioid use and harms.